Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance

GeneDx Holdings (NASDAQ:WGS) stock is trading higher on Tuesday.

The genetic testing company reported a third-quarter EPS loss of $(0.31), compared to $(1.64) reported a year ago, beating the consensus loss of $(0.50).

The company reported sales of $76.87 million, up 44% year over year, beating the consensus of $64.99 million.

Exome and genome test revenue grew to $60.0 million, an increase of 77% year-over-year and 18% sequentially.

Exome and genome test results volume grew to ...